Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)

Author(s): K. V. Gleixner, M. Mayerhofer, A. Vales, A. Gruze, G. Hormann, S. Cerny-Reiterer, E. Lackner, E. Hadzijusufovic, H. Herrmann, A. K. Iyer, M.-T. Krauth, W. F. Pickl, B. Marian, R. Panzer-Grumayer, C. Sillaber, H. Maeda, C. Zielinski, P. Valent.

Abstract:

Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most solid tumors and hematopoietic neoplasms and may be employed as a new therapeutic target as evidenced by experiments using specific siRNA and a Hsp32-targeting pharmacologic inhibitor. This Hsp-32 targeting drug, SMA-ZnPP, was found to inhibit the proliferation of neoplastic cells with IC50 values ranging between 1 and 50 μM. In addition, SMA-ZnPP induced apoptosis in all neoplastic cells examined. Furthermore, SMA-ZnPP was found to synergize with other targeted and conventional drugs in producing growth-inhibition. Resulting synergistic effects were observed in all tumor- and leukemia cells examined. Interestingly, several of the drug partners, when applied as single agents, induced the expression of Hsp32 in neoplastic cells, suggesting that synergistic effects resulted from SMA-ZnPPinduced ablation of a Hsp32-mediated survival-pathway that is otherwise used by tumor cells to escape drug induced apoptosis. Together, Hsp32 is an important survival factor and target in solid tumors and hematopoietic neoplasms, and may be used to optimize anticancer therapy by combining conventional or targeted drugs with Hsp32-inhibitors. Based on these data, it seems desirable to explore the value of Hsp32-targeting drugs as anti-cancer agents in clinical trials.

Keywords: Solid tumors, Leukemias, HO-1, Hsp32, SMA-ZnPP, targeted drugs

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 9
ISSUE: 5
Year: 2009
Page: [675 - 689]
Pages: 15
DOI: 10.2174/156800909789057024
Price: $58